Synopsys (SNPS) Is Down 9.4% After Activist Board Move And Expanded Samsung AI Chip Pact – Has The Bull Case Changed?

• In late May 2026, Synopsys reported second-quarter revenue of US$2,275.99 million with sharply lower net income of US$17.11 million, raised its full-year revenue and EPS guidance, expanded its AI-powered EDA and IP collaboration with Samsung Foundry across advanced 2nm and 3DIC nodes, and added Elliott’s Jesse Cohn to its board.
• Together, these developments highlight Synopsys’ twin pressures and opportunities: integrating Ansys and new AI offerings while an activist-backed board pushes for higher efficiency and profitability.
• We’ll now examine how the enlarged Samsung Foundry collaboration and activist involvement might reshape Synopsys’ existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Synopsys Investment Narrative Recap

To own Synopsys, you need to believe that demand for advanced chip design, simulation and IP will keep pulling its tools deeper into AI and multi-die workflows, while the Ansys integration and cost actions eventually translate strong top-line growth into healthier margins. The latest quarter’s profit drop keeps execution on integration and IP monetization as the key short term catalyst and risk, and the Samsung and Elliott updates do not materially change that near term focus.

The expanded Samsung Foundry collaboration at SAFE 2026 is most relevant here, because it reinforces Synopsys’ role at the leading edge of 2 nm and 3DIC design just as customers are seeking faster, AI-enabled design cycles. That strengthens the long term case that Synopsys can support more complex, higher value silicon and systems, but it also raises the stakes on whether the company can adapt its IP business model and cost base quickly enough to protect profitability.

Yet while the edge partnerships look impressive, investors should still be aware that Synopsys’ shift to more customized IP and complex delivery models could...

Read the full narrative on Synopsys (it's free!)

Synopsys' narrative projects $12.1 billion revenue and $1.9 billion earnings by 2029. This requires 14.7% yearly revenue growth and roughly an $0.8 billion earnings increase from $1.1 billion today.

Uncover how Synopsys' forecasts yield a $539.69 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community cluster between US$469.66 and US$559.61, underscoring how differently individual investors view Synopsys’ potential. Against that backdrop, the pressure on its IP segment to justify higher development spend and protect margins could have meaningful implications for how you judge those valuations and the company’s longer term earnings power.

Explore 5 other fair value estimates on Synopsys - why the stock might be worth as much as 18% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Synopsys research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Synopsys research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Synopsys' overall financial health at a glance.

Want Some Alternatives?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 12 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com